European Commission for the Control of Foot-and-Mouth Disease (EuFMD), Food and Agriculture of the United Nations, Rome, Italy; The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, United Kingdom.
Dept for the Environment, Howard Davis Fm, Trinity, Jersey, United Kingdom.
Vaccine. 2019 Feb 14;37(8):1007-1015. doi: 10.1016/j.vaccine.2018.12.064. Epub 2019 Jan 23.
Vaccines are commonly used to control Foot-and-Mouth Disease (FMD) in endemic regions and form an important part of contingency plans for FMD-free countries. Conventional FMD vaccines have numerous limitations, and the U.S. government supports the development of next-generation vaccines. In the U.S., vaccine efficacy is typically demonstrated through experimental vaccination and challenge of animals using the World Organization for Animal Health (OIE) standards. Although conventional challenge and immunogenicity studies provide useful information, they have limitations and results do not always accurately predict field performance. Consequently, there is a need to test next-generation vaccines under field conditions to gain a better understanding of field performance to inform policy decisions and support their viability as a commercial product. In June 2017, an expert consultation was organised to discuss and define an optimal field study design for novel FMD vaccines. Cattle were the primary species considered, although parallel strategies for swine and small ruminants were also discussed. Many methodological and logistical considerations in the study design were identified, including: (1) study site selection and the importance of baseline studies to understand exposure risk, (2) ethics of using a placebo and assessing equivalence with conventional vaccines, (3) merits of using individual randomised versus cluster randomised trials, (4) preventive versus reactive vaccination, and (5) methods of randomisation and blinding. The proposed optimal study design was a multicentre (i.e. farm), three-arm, double-blind randomised controlled trial comparing groups receiving the novel vaccine to a conventional vaccine group and a placebo group. Large farms in areas of high exposure risk were identified as ideal study sites, and the primary study outcome was susceptibility to disease or infection, during a six-month observation period, following a single dose of vaccine. This report provides a summary of the important issues to consider when designing a field efficacy study in livestock and proposes a study design that could be utilised for novel FMD vaccines.
疫苗通常用于控制口蹄疫(FMD)在流行地区,并形成无口蹄疫国家应急计划的重要组成部分。传统的口蹄疫疫苗有许多局限性,美国政府支持下一代疫苗的开发。在美国,疫苗的功效通常是通过实验性接种和使用世界动物卫生组织(OIE)标准对动物进行挑战来证明的。虽然常规的挑战和免疫原性研究提供了有用的信息,但它们存在局限性,结果并不总是准确预测现场表现。因此,需要在现场条件下测试下一代疫苗,以更好地了解现场性能,为决策提供信息,并支持其作为商业产品的可行性。2017 年 6 月,组织了一次专家协商,讨论和定义了一种新型口蹄疫疫苗的最佳现场研究设计。牛是主要考虑的物种,尽管也讨论了针对猪和小反刍动物的平行策略。在研究设计中确定了许多方法学和后勤方面的考虑因素,包括:(1)研究地点的选择以及进行基线研究以了解暴露风险的重要性,(2)使用安慰剂和评估与传统疫苗等效性的伦理问题,(3)使用个体随机对照与群组随机对照试验的优点,(4)预防性与反应性接种,以及(5)随机化和盲法的方法。提出的最佳研究设计是一个多中心(即农场)、三臂、双盲随机对照试验,比较接受新型疫苗的组与传统疫苗组和安慰剂组。高暴露风险地区的大型农场被确定为理想的研究地点,主要研究结果是在六个月的观察期内,单次接种疫苗后对疾病或感染的易感性。本报告总结了在牲畜中设计现场功效研究时需要考虑的重要问题,并提出了一种可用于新型口蹄疫疫苗的研究设计。